Seroquel XR® – Launch of New Indication for MDD & New 150 mg (30’s) Pack
Seroquel XR 150mg® is now launched and is indicated as adjunctive therapy in the treatment of resistant major depressive disorder. It should be administered once daily in the evening, with or without food, and swallowed whole and not split, chewed or crushed.
The initial dose for major depressive disorder should begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments can be made upwards or downwards within the recommended dose range of 50-300mg depending upon the clinical response and tolerability of the patient.
Seroquel XR offers a treatment option for: schizophrenia, mania and depression in bipolar disorder; major depressive disorder (MDD).
For any Medical queries: 011 797 6000 or SA.MEAMedinfo@astrazeneca.com